Zimmer Biomet (NYSE:ZBH) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Zimmer Biomet (NYSE:ZBH) from a hold rating to a buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other equities analysts also recently commented on the stock. Weiss Ratings upgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Barclays raised shares of Zimmer Biomet to a “hold” rating in a research report on Wednesday, October 7th. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Royal Bank Of Canada boosted their target price on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Finally, Truist Financial increased their target price on Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $104.47.

Zimmer Biomet Stock Down 3.0%

Shares of ZBH opened at $94.54 on Friday. The company has a market cap of $18.03 billion, a PE ratio of 23.00, a P/E/G ratio of 2.27 and a beta of 0.49. The business has a fifty day moving average of $94.86 and a 200 day moving average of $91.70. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $103.70. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. During the same period in the previous year, the firm earned $2.07 earnings per share. Zimmer Biomet’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts expect that Zimmer Biomet will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is 23.36%.

Insider Activity

In other Zimmer Biomet news, insider Chad Phipps sold 3,000 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of large investors have recently made changes to their positions in ZBH. BlackRock Inc. purchased a new stake in Zimmer Biomet in the second quarter valued at approximately $1,344,282,000. Primecap Management Co. CA acquired a new stake in Zimmer Biomet during the 2nd quarter worth $328,578,000. Bank of America Corp DE purchased a new stake in Zimmer Biomet in the second quarter valued at approximately $187,480,000. Equity Investment Corp acquired a new stake in shares of Zimmer Biomet during the second quarter worth about $144,748,000. Finally, Legal & General Group Plc acquired a new stake in shares of Zimmer Biomet during the second quarter worth $126,167,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.